GlassScriptPhysician profile
Paul A Bell
NPI 1609894930
$4,695.90
in general payments reported to CMS, 2019-2025
28 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 81% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $113 · 2021: $258 · 2022: $602 · 2023: $1,289 · 2024: $1,158 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,155.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,085.38 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $739.38 | 2019-2025 | Nucala |
| Optinose US, INC. | $368.70 | 2019-2025 | |
| Inspire Medical Systems, INC. | $193.64 | 2023-2025 | Inspire |
| Kaleo, INC. | $138.60 | 2023-2024 | Auvi-Q |
| Grifols USA, LLC | $108.39 | 2022-2025 | Xembify |
| Bausch & Lomb Americas INC. | $94.58 | 2024 | Miebo, Xiidra |
| Alk-Abello, INC | $88.20 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Takeda Pharmaceuticals U.S.A., INC. | $86.84 | 2021-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $85.34 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $74.36 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $57.11 | 2022-2024 | Ryaltris |
| Genentech USA, INC. | $55.77 | 2023 | Xolair |
| Amgen INC. | $54.69 | 2024 | Tezspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $41.51 | 2022-2023 | Airduo Digihaler |
| Carl Zeiss Meditec Cataract Technology INC. | $32.30 | 2022 | |
| Integra Lifesciences Corporation | $28.55 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Biocryst US Sales Co., LLC | $27.97 | 2025 | Orladeyo |
| Lilly USA, LLC | $26.01 | 2025 | Zepbound |
| Phathom Pharmaceuticals, INC. | $24.24 | 2024 | Voquezna |
| Aerin Medical INC. | $23.44 | 2021 | |
| Phadia US INC. | $21.21 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $19.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.92 | 2025 | Tezspire |
| Mylan Pharmaceuticals INC. | $18.05 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.98 | 2020 | |
| Smith+Nephew, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.